Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says

Association for Accessible Medicines report highlights continuing upward trend of cost savings from generic drugs; trade group argues legislative proposals addressing restricted distribution misuse are key to accelerating savings.